Objectives: The importance of detecting human papillomavirus (HPV) in head and neck squamous cell carcinoma (HNSCC) has resulted in a growing expectation for HPV testing of clinical samples. Although testing protocols vary, most pertain to primary tumor biopsies/resections. Testing of fine-needle aspirates and core biopsies (FNACBs) is advantageous, but it is unclear whether technical and biological factors adversely affect the fidelity of HPV detection in these samples. Methods: Data was collected for 85 patients with regionally metastatic HNSCC that had undergone FNACB with HPV analysis as part of clinical care. HPV testing consisted of p16 immunostaining and HPV in situ hybridization (ISH). The FNACBs were compared with the subsequent biopsies/resections for HPV status. Results: p16 staining was present in 60 cases (71%). p16 positivity was predictive of oropharyngeal origin (p < 0.001) and correlated with the presence of HPV by ISH (98% correlation). On comparison of the metastases and primary cancers, the HPV status was concordant in 58 of 59 cases (98%). Conclusions: For patients with metastatic HNSCC, p16 staining reliably reflects the HPV status of the primary tumor. p16 staining of FNACBs may obviate the need for more invasive sampling of the primary cancer solely for the purpose of HPV testing.

Keywords:
Aspiration biopsy, Fine-needle aspiration, Human papillomavirus, Head and neck
1.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
2.
Singhi AD, Westra WH: Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116:2166-2173.
3.
D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
4.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
5.
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
6.
Umudum H, Rezanko T, Dag F, Dogruluk T: Human papillomavirus genome detection by in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. Cancer 2005;105:171-177.
7.
Begum S, Gillison ML, Nicol TL, Westra WH: Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:1186-1191.
8.
Zhang MQ, El-Mofty SK, Davila RM: Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer 2008;114:118-123.
9.
Chen ZW, Weinreb I, Kamel-Reid S, Perez-Ordonez B: Equivocal p16 immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status. Head Neck Pathol 2012;6:422-429.
10.
Lewis JS Jr: P16 immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012;6(suppl 1):S75-82.
11.
Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH: Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003;9:6469-6475.
12.
Hoffmann M, Ihloff AS, Gorogh T, Weise JB, Fazel A, Krams M, Rittgen W, Schwarz E, Kahn T: P16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010;127:1595-1602.
13.
Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML: Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012;36:945-954.
14.
El-Naggar AK, Westra WH: P16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 2012;34:459-461.
15.
Begum S, Cao D, Gillison M, Zahurak M, Westra WH: Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005;11:5694-5699.
16.
Ruzevick J, Olivi A, Westra WH: Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neurooncol 2013;112:449-454.
17.
Bishop JA, Ogawa T, Chang X, Illei PB, Gabrielson E, Pai SI, Westra WH: HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol 2012;36:142-148.
18.
Mehrad M, Zhao H, Gao G, Wang X, Lewis JS Jr: Transcriptionally active human papillomavirus is consistently retained in the distant metastases of primary oropharyngeal carcinomas. Head Neck Pathol 2014;8:157-163.
19.
Weichert W, Schewe C, Denkert C, Morawietz L, Dietel M, Petersen I: Molecular HPV typing as a diagnostic tool to discriminate primary from metastatic squamous cell carcinoma of the lung. Am J Surg Pathol 2009;33:513-520.
20.
de Braud F, al-Sarraf M: Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. Semin Oncol 1993;20:273-278.
21.
Witt BL, Schmidt RL: Ultrasound-guided core needle biopsy of salivary gland lesions: a systematic review and meta-analysis. Laryngoscope 2014;124:695-700.
22.
Novoa E, Gurtler N, Arnoux A, Kraft M: Role of ultrasound-guided core-needle biopsy in the assessment of head and neck lesions: a meta-analysis and systematic review of the literature. Head Neck 2012;34:1497-1503.
23.
Smith DF, Maleki Z, Coughlan D, Gooi Z, Akpeng B, Ogawa T, Bishop JA, Frick KD, Agrawal N, Gourin CG, Ha PK, Koch WM, Richmon JD, Westra WH, Pai SI: Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay. Oral Oncol 2014;50:600-604.
24.
Bishop JA, Maleki Z, Valsamakis A, Ogawa T, Chang X, Pai SI, Westra WH: Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol 2012;120:18-25.
25.
Solomides CC, Bibbo M, Wang ZX: Assessment of fine-needle aspiration specimen adequacy for high-risk HPV detection and genotyping in oropharyngeal squamous cell carcinoma. Acta Cytol 2012;56:196-198.
26.
Guo M, Khanna A, Dhillon J, Patel SJ, Feng J, Williams MD, Bell DM, Gong Y, Katz RL, Sturgis EM, Staerkel GA: Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma. Cancer Cytopathol 2014;122:96-103.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.